Catabasis Pharmaceuticals publishes results

Catabasis Pharmaceuticals Inc. (Nasdaq: CATB) published positive results from a Phase 1 study of its Duchenne muscular dystrophy treatment edasalonexent in the Journal of Clinical Pharmacology. Shares of the biopharmaceutical gained 82 cents to close at $4.97.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.